6月26日，康方生物盘中下跌3.16%，报82.85港元，成交额3.75亿港元，股价持续承压逼近52周低点80.2港元。消息面上，公司此前于ASCO公布依沃西HARMONi-6 OS阳性数据后持续遭遇获利了结，股价较数据公布后高点累计跌幅已逾30%，尽管董事会批准最多2亿港元回购计划及管理层拟增持不超过5000万港元，短期抛压仍未消化。同板块中信达生物跌1.25%、荣昌生物跌0.86%，生物科技板块整体偏弱，行业beta拖累叠加个股利好兑现后的筹码松动共同加剧调整压力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.